DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 5,981,489 Stevenson Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 5,981,489 Stevenson Et Al USOO5981489A United States Patent (19) 11 Patent Number: 5,981,489 Stevenson et al. (45) Date of Patent: Nov. 9, 1999 54) NON-AQUEOUS PROTIC PEPTIDE Okada, et al., “Preparation of Three-Month Depot Injectable FORMULATIONS MicroSpheres of Leuprorelin Acetate Using Biodegradable Polymers”, Pharmaceutical Research, 11/8, pp. 1143–1147 75 Inventors: Cynthia L. Stevenson, Mountain View; (1994). Sally A. Tao, San Jose; Steven J. Okada, et al., “New Degradation Product of Prestrelski, Mountain View; James B. Des-Gly'-NH-LH-RH-Ethylamide (Fertirelin) in Aque Eckenhoff, deceased, late of Los Altos, ous Solution”, J. of Pharmaceutical Sciences, 80/2, pp. by Bonnie J. Eckenhoff, executrix; 167–170 (1991). Jeremy C. Wright, Los Altos; John J. Oyler, et al., “Characterization of the Solution Degradation Leonard, Jr., Cupertino, all of Calif. Products of Histrelin, a Gonadotropin Releasing Hormone (LH/RH) Agonist”, J. of Pharmaceutical Sciences, 80/3, pp. 73 Assignee: Alza Corporation, Palo Alto, Calif. 271-275 (1991). Powell, et al., “Peptide Liquid Crystals: Inverse Correlation 21 Appl. No.: 08/874,680 of Kinetic Formation and Thermodynamic Stability in Aque ous Solution”, Pharmaceutical Research, 11/9, pp. 22 Filed: Jun. 13, 1997 1352–1354 (1994). Related U.S. Application Data Powell, et al., “Parenteral Peptide Formulations: Chemical and Physical Properties of Native Luteinizing Hormone-R- 60 Provisional application No. 60/022,129, Jul. 3, 1996. eleasing Hormone (LHRH) and Hydrophobic Analogues in 51 Int. Cl. ........................... A61K38/00; CO7K5/00; Aqueous Solution”, Pharmaceutical Research, 8/10, pp. CO7K 7/00 1258–1263 (1991). 52 U.S. Cl. ............................. 514/15; 530/313; 530/328 Powers, et al., “Solution Behavior of Leuprolide Acetate, an 58 Field of Search ........................ 514/15, 12; 530/313, LHRH Agonist, as Determined by Circular Dichroism Spec 530/328 troscopy”, Intl. J. of Pharmaceutics, 108, pp. 49-55 (1994). Shi, et al., “Long-Term Stability of Aqueous Solutions of 56) References Cited Luteinizing Hormone-Releasing Hormone ASSessed by an In-Vitro Bioassay and Liquid Chromatography”, J. of Phar U.S. PATENT DOCUMENTS maceutical Sciences, 73/6, pp. 819-821 (1984). 3,914,412 10/1975 Gendrich et al. ....................... 424/177 Toguchi, “Pharmaceutical Manipulation of Leuprorelin 4,547,370 10/1985 Roeske ...................................... 514/15 Acetate to Improve Clinical Performance”, J. of Intl. Medi 4,661,472 4/1987 Rivier et al. .............................. 514/15 4,689,396 8/1987 Roeske et al. .......................... 530/313 cal Research, 18, pp. 35-41 (1990). 4,851,385 7/1989 Roeske ...................................... 514/15 Factrel (gonadorelin HCl for subcutaneous or IV injection), 5,034,229 7/1991 Magruder et al. ... 424/422 Physician's Desk Reference, 50th Edition, pp. 2877–2878 5,057,318 10/1991 Magruder et al. ... ... 424/438 (1996). 5,110,596 5/1992 Magruder et al. ... 424/438 Lupron (leuprolide acetate for Subcutaneous injection), Phy 5,198,533 3/1993 Schally et al. .......................... 530/313 sician's Desk Reference, 50th Edition, pp. 2555-2556 5,480,868 1/1996 Kamei et al. ............................. 514/15 (1996). Lupron Depot (leuprolide acetate for depot Suspension), FOREIGN PATENT DOCUMENTS Physician's Desk Reference, 50th Edition, pp. 2556-2562 0312052 4/1989 European Pat. Off.. (1996). 0432479 6/1991 European Pat. Off. ......... A61K 9/48 Lutrepulse (gonadorelin acetate for IV injection), Physi 0510731 10/1992 European Pat. Off.. cian's Desk Reference, 50th Edition, pp.980–982 (1996). WO92/207 11 11/1992 WIPO. 94O6452 3/1994 WIPO ............................ A61K 37/02 Zoladex (goserelin acetate implant), Physician's Desk Ref WO94/1902O 9/1994 WIPO. erence, 50th Edition, pp. 2858–2861 (1996). WO95/OO168 1/1995 WIPO. WO95/04540 2/1995 WIPO. Primary Examiner Avis M. Davenport WO97/27840 8/1997 WIPO. Attorney, Agent, or Firm Mary Ann Dillahunty; Steven F. Stone; Pauline Ann Clarke OTHER PUBLICATIONS 57 ABSTRACT Fu Lu, et al., “Percutaneous Absorption Enhancement of Leuprolide”, Pharmaceutical Research, 9/12, pp. This invention relates to Stable non-aqueous protic formu 1575-1576 (1992). lations of peptide compounds. These Stable formulations Helm, et al., “Stability of Gonadorelin and Triptorelin in comprise peptide in non-aqueous protic Solvent. They may Aqueous Solution”, Pharmaceutical Research, 7/12, pp. be Stored at elevated temperatures for long periods of time 1253–1256 (1990). and are especially useful in implantable delivery devices for Johnson, et al., “Degradation of the LH-RHAnalog Nafare long term delivery of drug. lin Acetate in Aqueous Solution”, Intl. J. of Pharmaceutics, 31, pp. 125-129 (1986). 63 Claims, 11 Drawing Sheets U.S. Patent 5,981,489 OO'O, U.S. Patent Nov. 9, 1999 Sheet 2 of 11 5,981,489 PROCESSING METHOD: SEC O.6O O.55 O.50 O.45 O.40 O.35 2 O.30 O.25 O.2O 0.15 O. 10 O.O5 O.OO O.OO 1.O.OO 2O.OO 3O.OO 4O.OO MINUTES FIG. 2 U.S. Patent Nov. 9, 1999 Sheet 4 of 11 5,981,489 - O SE to 37°C d 0 50°C 65°C R 9 8OC Z TIME (MONTHS) FIG. 4 U.S. Patent Nov. 9, 1999 Sheet 5 of 11 5,981,489 120 g 96 LEUPROLIDE 60 0 % CHEMICAL a % Di/TRIMER 0 MASS BALANCE 4.O TIME (MONTHS) FIG. 5 U.S. Patent 5,981,489 092OOZ …-•* O O C O 09O O'06 3 3 V BOITOST % ~~~~====O'O, U.S. Patent NOV. 9 1999 Sheet 8 of 11 5,981,489 00€ OGZ OOZ (SAVCI)EW11 8"5)|–| 09 yO'0 U.S. Patent Nov. 9, 1999 Sheet 9 of 11 5,981,489 CONC. (% DRUG REMAINING) S. 3 3 s 3 8 8 t o tC S. 3 3 3s is it 8 | 8 3 A. 8 ON. 3 OO V o OTH ABOSNWBBC SWAL? U.S. Patent Nov. 9, 1999 Sheet 11 of 11 5,981,489 CONCENTRATION 3 S. 8 8 9 e 9Nst OO 2 O H. m 2. L O Z O O O 3 & N 8 3 3 Old HA9 ONWHLSO SV Al?o 5,981,489 1 2 NON-AQUEOUS PROTIC PEPTIDE 20. Lupron (leu prolide acetate for Subcutaneous FORMULATIONS injection), Physician's Desk Reference, 50th Edition, pages 2555-2556 (1996). CROSS-REFERENCE TO RELATED 21. Lupron depot (leu prolide acetate for depot APPLICATIONS 5 Suspension), Physician's Desk Reference, 50th Edition, pages 2556-2562 (1996). This application claims priority under 35 U.S.C. 119(e) to 22. “Pharmaceutical Manipulation of Leuprorelin Acetate U.S. application Ser. No. 60/022,129 filed Jul. 3, 1996, the to Improve Clinical Performance', H. Toguchi, J. of disclosure of which is incorporated herein by reference. Intl. Medical Research, 18, pages 35-41 (1990). 23. “Long-Term Stability of Aqueous Solutions of Lutein FIELD OF THE INVENTION 1O izing Hormone-Releasing Hormone ASSessed by an This invention relates to stable non-aqueous protic for In-Vitro Bioassay and Liquid Chromatography', Y. F. mulations of peptide compounds. In particular, formulations Shi, R. J. Sherins, D. Brightwell, J. F. Gallelli, D. C. with high concentrations of peptide compounds are pro Chatterji, J. of Pharmaceutical Sciences, 73/6, pages vided. 819–821 (1984). 15 24. “Peptide Liquid Crystals: Inverse Correlation of BACKGROUND OF THE INVENTION Kinetic Formation and Thermodynamic Stability in Aqueous Solution”, M. F. Powell, J. Fleitman, L. M. References Sanders, V. C. Si, Pharmaceutical Research, 11/9, The following references are referred to by numbers in 20 pages 1352–1354 (1994). brackets (I) at the relevant portion of the specification. 25. “Solution Behavior of Leuprolide Acetate, an LHRH 1. Zoladex (goserelin acetate implant), Physician's Desk Agonist, as Determined by Circular Dichroism Reference, 50th Edition, pages 2858-2861 (1996). Spectroscopy”, M. E. Powers, A. Adejei, M. Y. Fu Lu, 2. U.S. Pat. No. 3,914,412, issued Oct. 21, 1975. M. C. Manning, Intl. J. of Pharmaceutics, 108, pages 25 49–55 (1994). 3. U.S. Pat. No. 4,547,370, issued Oct. 15, 1985. 26. “Preparation of Three-Month Depot Injectable Micro 4. U.S. Pat. No. 4,661,472, issued Apr. 28, 1987. Spheres of Leuprorelin Acetate Using Biodegradable 5 U.S. Pat. No. 4,689,396, issued Aug. 25, 1987. Polymers”, Pharmaceutical Research, 11/8, pages 6 U.S. Pat. No. 4,851,385, issued Jul 25, 1989. 1143–1147 (1994). The disclosure of each of the above publications, patents 7. U.S. Pat. No. 5,198,533, issued Mar. 30, 1993. or patent applications is hereby incorporated by reference in 8. U.S. Pat. No. 5,480,868, issued Jan. 2, 1996. its entirety to the same extent as if the language of each 9. WO92120711, published Nov. 26, 1992. individual publication, patent and patent application were 10. WO95/00168, published Jan. 5, 1995. Specifically and individually incorporated by reference. 11. WO95/04540, published Feb. 16, 1995. 35 Luteinizing hormone-releasing hormone (LHRH), also 12. "Stability of Gonadorelin and Triptorelin in Aqueous known as gonadotropin releasing hormone (GnRH), is a Solution', V. J. Helm, B. W. Muller, Pharmaceutical decapeptide with the Structure: Research, 7/12, pages 1253–1256 (1990). 13. “New Degradation Product of Des-Gly'-NHLH pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro Gly-NH. RH-Ethylamide (Fertirelin) in Aqueous Solution”, J. 40 It is Secreted by the hypothalamus and binds to receptors on Okada, T. Seo, F. Kasahara, K. Takeda, S. Kondo, J. of the pituitary gland, releasing luteinizing hormone (LH) and Pharnaceutical Sciences, 80/2, pages 167-170 (1991). follicle stimulating hormone (FSH). LH and FSH stimulate 14. “Characterization of the Solution Degradation Product the gonads to Synthesize Steroid hormones. Numerous ana of Histrelin, a Gonadotropin Releasing Hormone logs of LHRH are known, including peptides related to (LHRH) Agonist”, A.
Load more

Recommended publications
  • Fully Automated Dried Blood Spot Sample Preparation Enables the Detection of Lower Molecular Mass Peptide and Non-Peptide Doping Agents by Means of LC-HRMS
    Analytical and Bioanalytical Chemistry (2020) 412:3765–3777 https://doi.org/10.1007/s00216-020-02634-4 RESEARCH PAPER Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS Tobias Lange1 & Andreas Thomas1 & Katja Walpurgis1 & Mario Thevis1,2 Received: 10 December 2019 /Revised: 26 March 2020 /Accepted: 31 March 2020 # The Author(s) 2020 Abstract The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone–releasing peptides (GHRPs), argu- ably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters.
    [Show full text]
  • The Use of an Intravaginal Triptorelin Gel to Induce Ovulation in the Mare
    THE USE OF AN INTRAVAGINAL TRIPTORELIN GEL TO INDUCE OVULATION IN THE MARE by CHELSEA D. SINCLAIR B.S., Clemson University, 2013 A THESIS submitted in partial fulfillment of the requirements for the degree MASTER OF SCIENCE Department of Animal Sciences and Industry College of Agriculture KANSAS STATE UNIVERSITY Manhattan, Kansas 2016 Approved by: Major Professor Dr. Joann M. Kouba Copyright CHELSEA D. SINCLAIR 2016 Abstract The objective of these studies was to investigate the efficacy of an intravaginal triptorelin acetate (TA) gel as an ovulation-inducing agent in mares. In Exp 1, 24 mares were stratified by parity and age and randomly assigned to 3 treatment groups receiving either: 5 mL TA gel (500 μg TA; TA5), 10 mL TA gel (1,000 μg TA; TA10), or 5 mL vehicle gel only (CON). Following the appearance of a follicle ≥ 25 mm, blood samples were obtained every 24 h until treatment administration for measurement of luteinizing hormone (LH) concentrations. Once a follicle ≥ 35 mm in diameter was detected, treatment was administered intravaginally. Following treatment, blood samples were collected and ovaries were scanned via transrectal ultrasonography every 12 h until 48 h post-ovulation. Both TA5 and TA10 tended (P = 0.08) to experience a brief surge in LH by 12 h post-treatment. Regarding LH concentrations, there was a significant (P < 0.005) treatment by time interaction. The interval from treatment to ovulation was not different (P > 0.05) between groups, nor was there a difference (P > 0.05) in the percentage of mares ovulating within 48 h of treatment administration.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,235,712 B1 Stevenson Et Al
    US006235.712B1 (12) United States Patent (10) Patent No.: US 6,235,712 B1 Stevenson et al. (45) Date of Patent: May 22, 2001 (54) NON-AQUEOUS POLARAPROTIC PEPTIDE Helm, et al., “Stability of Gonadorelin and Triptorelin in FORMULATIONS Aqueous Solution”, Pharm. Res., 7/12, pp. 1253-1256 (1990). (75) Inventors: Cynthia L. Stevenson; Steven J. Johnson, et al., “Degradation of the LH-RHAnalog Nafare Prestrelski, both of Mountain View, CA lin Acetate in Aqueous Solution”, Intl. J. Pharm., 31, pp. (US) 125-129 (1986). 73) Assignee:9. ALZA Corporation,p Mountain View, Lupron (leuprolide acetate for Subcutaneous injection), Phy CA (US) sician's Desk Ref, 50th Ed., pp. 2555-2556 (1996). Lupron Depot (leuprolide acetate for depot Suspension), * ) Notice: Subject to anyy disclaimer, the term of this Physician's Desk Ref, 50th Ed., pp. 2556-2562 (1996). patent is extended or adjusted under 35 Lutrepulse (gonadorelin acetate for IV injection), Physi U.S.C. 154(b) by 0 days. cian's Desk Ref, 50th Ed., pp.980–982 (1996). Okada, et al., “New Degradation Product of (21) Appl. No.: 09/514,951 Des-Gly'-NH-LH-RH-Ethylamide (Fertirelin) in Aque (22) Filed: Feb. 28, 2000 ous Solution”, J. Pharm. Sci., 80/2, pp. 167–170 (1991). Okada, et al., “Preparation of Three-Month Depot Injectable Related U.S. Application Data MicroSpheres of Leuprorelin Acetate Using Biodegradable Polymers”, Pharm. Res., 11/8, pp. 1143–1147 (1994). (62) Division of application No. 09/293,839, filed on Apr. 19, 1999, now Pat. No. 6,124,261, which is a continuation of Oyler, et al., “Characterization of the Solution Degradation application No.
    [Show full text]
  • Reproductionresearch
    REPRODUCTIONRESEARCH Relationships between FSH patterns and follicular dynamics and the temporal associations among hormones in natural and GnRH-induced gonadotropin surges in heifers J M Haughian, O J Ginther1,KKot1 and M C Wiltbank Department of Dairy Science, 1675 Observatory Drive and 1Department of Animal Health and Biomedical Sciences, University of Wisconsin, Madison, Wisconsin 53706, USA Correspondence should be addressed to M C Wiltbank; Email: [email protected] Abstract Preovulatory LH and FSH surges and the subsequent periovulatory FSH surge were studied in heifers treated with a single injection of GnRH (100 mg, n 5 6) or saline (n 5 7). Blood samples were collected every hour from 6 h before treatment until 12 h after the largest follicle reached $8.5 mm (expected beginning of follicular deviation). The GnRH-induced preovulatory LH and FSH surges were higher at the peak and shorter in duration than in controls, but the area under the curve was not different between groups. The profiles of the preovulatory LH and FSH surges were similar within each treatment group, suggesting that the two surges involved a common GnRH-dependent mechanism. Concentrations of FSH in controls at the nadir before the preovulatory surge and at the beginning and end of the periovulatory surge were not significantly different among the three nadirs. A relationship between variability in the periovulatory FSH surge and number of 5.0 mm follicles was shown by lower FSH concentrations during 12–48 h after the beginning of the surge in heifers with more follicles (11.0 6 1.0 follicles (mean6S.E.M.) n 5 7) than in heifers with fewer follicles (5.7 6 0.4, n 5 6).
    [Show full text]
  • Investigation of the Presence of Gnrh and Gnrh-R System in Bovine
    Investigation of the Presence of GnRH and GnRH-R System in Bovine Oocytes, Sperm and Early Embryos and their Functional Role in Reproduction by USWATTELIYANARALALAGE FELICIA RUWANIE PERERA B.V.Sc., University of Peradeniya, Peradeniya, Sri Lanka, 2001 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE STUDIES (Animal Science) THE UNIVERSITY OF BRITISH COLUMBIA (VANCOUVER) April 2010 ©Uswatteliyanaralalage Felicia Ruwanie Perera, 2010 ABSTRACT The objectives of this study were to investigate: 1) the effect of GnRH agonist on oocyte maturation, sperm function and fertilization, 2) the presence of GnRH-R in bovine oocytes, sperm and early embryos. To examine the effect of GnRH agonist on sperm function, sperm were incubated in modified Tyrode’s medium with 0, 0.2, 0.4, 0.8 and 1.2 µgmL -1 of buserelin and with1 -1 µgmL P4 for 3 h. Acrosome status in each group was assessed at 0 h and 3 h. For zona- binding assay, in vitro matured oocytes were co-incubated with sperm in different concentrations of buserelin and P 4 for 4 h and the zona-bound sperm in each treatment group was determined. Acrosome reacted percentage were higher in sperm treated with 0.4, 0.8 µgmL -1 buserelin than the control group (p<0.001). The number of zona-bound sperm were higher in 0.8 µgmL -1 buserelin compared to negative control (p<0.01). Effect of buserelin was blocked by antide. To investigate the effect of GnRHa on maturation of bovine oocytes 0.8 µgmL -1 buserelin was added to the in vitro maturation media and maturation rate was obtained after 24 h against control groups with FSH and without FSH.
    [Show full text]
  • Reproductive Endocrinology of the Dog
    Reproductive endocrinology of the dog Effects of medical and surgical intervention Jeffrey de Gier 2011 Cover: Anjolieke Dertien, Multimedia; photos: Jeffrey de Gier Lay-out: Nicole Nijhuis, Gildeprint Drukkerijen, Enschede Printing: Gildeprint Drukkerijen, Enschede De Gier, J., Reproductive endocrinology of the dog, effects of medical and surgical intervention, PhD thesis, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands Copyright © 2011 J. de Gier, Utrecht, The Netherlands ISBN: 978-90-393-5687-6 Correspondence and requests for reprints: [email protected] Reproductive endocrinology of the dog Effects of medical and surgical intervention Endocrinologie van de voortplanting van de hond Effecten van medicamenteus en chirurgisch ingrijpen (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof.dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op dinsdag 20 december 2011 des middags te 12.45 uur door Jeffrey de Gier geboren op 14 mei 1973 te ’s-Gravenhage Promotor: Prof.dr. J. Rothuizen Co-promotoren: Dr. H.S. Kooistra Dr. A.C. Schaefers-Okkens Publication of this thesis was made possible by the generous financial support of: AUV Dierenartsencoöperatie Boehringer Ingelheim B.V. Dechra Veterinary Products B.V. J.E. Jurriaanse Stichting Merial B.V. MSD Animal Health Novartis Consumer Health B.V. Royal Canin Nederland B.V. Virbac Nederland B.V. Voor mijn ouders
    [Show full text]
  • VETERINARY PEPTIDES Peptides in Veterinary Medicine
    VETERINARY PEPTIDES Peptides in Veterinary Medicine PEPTIDES IN VETERINARY MEDICINE Bachem offers a choice of generic peptides for use as active ingredients in veterinary medicine, amongst them gonadorelin and gonadorelin agonists and antagonists. For a compilation of our peptide APIs please see page 20. Our offer is comple- mented by the corresponding peptides in research quality to be found on page 23-25. Additionally, we provide the anesthetics etomidate and pro- pofol as non-peptide generic APIs for the veterinary practice, please see page 21. Introduction Peptide-based drugs are especially indicated for treating animals used in A considerable number of peptides applied food production, as they are highly active as therapeutics or diagnostics in humans is compounds which require only very small also used for various indications in veteri- doses. Additionally, they are metabolized nary medicine. more readily than organic compounds, Peptides are relatively expensive drugs which reduces the risk of contamination of which, in most cases, can’t be applied orally, the milk, eggs, or meat of the treated animal but these shortcomings are often out- by the unmetabolized pharmaceutical and/ weighed by their advantages. or its degradation products. There is also a vast market for peptide drugs in the treatment of companion ani- mals and horses. Pets can suffer from most diseases of civilization that affect humans. Accordingly, diabetes has become a grow- ing problem with dogs and cats in recent years due to their increasing life expectancy PEPTIDE in combination with obesity and lack of exercise. At the same time, owners are more THERAPEUTICS willing to pay for medication and therapies to increase the length and quality of life of Administration of synthetic peptides their diseased pets.
    [Show full text]
  • WO 2020/0951S3 A1 14 May 2020 (14.05.2020) I 4 P Cl I P C T
    (12) INTERNATIONAL APPLICATION PI;BLISHED I. NDER THE PATENT COOPERATION TREATY (PCT) (19) World intellectual Propertv Organraation llIIlIIlllIlIlllIlIllIllIllIIIIIIIIIIIIIIIIIIIIIIllIlIlIlIllIlllIIllIlIIllllIIIIIIIIIIIIIIIIIII International Bureau (10) International Publication Number (43) International Publication Date WO 2020/0951S3 A1 14 May 2020 (14.05.2020) I 4 P Cl I P C T (51) International Patent Classification: MC. MK, MT. M., NO, PL, PT, RO, RS. SE. SI. SK. SM, A6JK3J/4166 (2006.01) A6/K&/5/t)6 (200G 01) TR). OAPI (BF, BJ, CF, CG, CI. CYI. GA, GN, GQ. GW. AGJK39/00(2006 01) C07K/6/28 (2006 01) KM,:vIL. MR, NE. SN, TD, TG) A6JP35/00(200G 01) AGJK38/68 (2019 Ol) Published: (21) International Application tiumber: »iili nrternatinrral seair 6 repurt 14rt 2113&i PCT/IB2019/059459 m Alar/ and &ilnte, the mternat»rrral app/icramn as fihrl (22) International Filing Date: crmiamerl en/«i rrr grevscale a&irl is rivrnhihiefur d«ii nlrrarl 04 November 2019 (04,11.2019) /rum P) TES"/;ST'OPE (25) Filing Langurrge: Enghsh (26) Public&stion Language: Enghsh (30) Priority Data: (&2/755.944 05 Not en&ber 2018105.11 20)8) US (i2/882.424 02 Auknrst 2019 (02 08.2019) US (71) Applicants: PFIZER INC. [US/L S], 233 East 42nd Street. Neve York. Ncw York 10017 (US). MERCK PATENT GMBH [DE/DE], Frankfurter Strasse 250, G4293 Dmm- stadi (DE) NEKTAR THERAPEUTICS [US/US]. 435 Nlission Ba) Boulmard South. Suite 100. San Francis- co, California 94158 (US). ASTELLAS PHARMA INC. f JP/JP], 2-5-1. Nihonbashi-Honcho, Chuo-Ku, Tokv o (JP) (72) Inventors: BOSHOFF, Christoffel Hendrik; c/o PFIZER INC, 235 East 42nd Street Neu York.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Gonadorelin Acetate May Be Produced Under a Variety of Names, Based on the Country Where the Synthesized Version of This Peptide Was Produced
    (Click here to read our disclaimer) Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NHsub2 Gonadorelin acetate may be produced under a variety of names, based on the country where the synthesized version of this peptide was produced. Potential branding for this peptide include lutenizing hormone-releasing factor dihydrochloride, like lutenizing hormone-releasing hormone,. This hormone is used by an animal’s body as a diagnostic aid that assists with hypothalamic- pituitary axis function. Some studies have also looked into the potential use of the synthesized version of this peptide as an infertility therapy agent. When produced by an animal’s body gonadorelin acetate acts as a natural gonadotropin releasing hormone (GnRH) which is primarily used as a means of synthesizing and releasing luteinizing hormone throughout the body from the anterior pituitary gland. This chemical can also act as a follicle stimulating hormone by increasing production of this chemical, though research has indicated that this behavior occurs to a much lesser degree. Research often centers around applying this chemical in prepubertal female test subjects as a means to control or eradicated gonadal function disorders that may require an additional LH or FSH response from the body. Responses to Gonadorelin in Holstein Heifers LH and FSH concentrations in heifers were monitored after intramuscular applications of fertirelin acetate and GnRH products including gonadorelin acetate. • Each heifer was exposed to nine applications of each chemical for 8-16 day cycles. Groups were exposed to buserelin, gonadorelin acetate or fertirelin acetate. • After these applications blood samples were drawn 1-8 hours later to log the responses to these chemicals and the different reactions between them.
    [Show full text]
  • Osmotic Stress and Cryoinjury of Koala Sperm: an Integrative Study of The
    REPRODUCTIONRESEARCH The absence of corpus luteum formation alters the endocrine profile and affects follicular development during the first follicular wave in cattle Ken-Go Hayashi1, Motozumi Matsui2, Takashi Shimizu1, Natsuko Sudo1, Ayako Sato1, Koumei Shirasuna1, Masa Tetsuka3, Katsuya Kida4, Dieter Schams5 and Akio Miyamoto1 1Graduate School of Animal and Food Hygiene, 2Department of Clinical Veterinary Science, 3Department of Agricultural and Life Science and 4Field Center of Animal Science and Agriculture, Obihiro University of Agriculture and Veterinary Medicine, Obihiro 080-8555, Japan and 5Institute of Physiology, Technical University of Munich, Freising-Weihenstephan 85350, Germany Correspondence should be addressed to M Matsui; Email: [email protected] K-G Hayashi is now at Reproductive Biology Research Unit, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki 305-8602, Japan Abstract We previously established a bovine experimental model showing that the corpus luteum (CL) does not appear following aspiration of the preovulatory follicle before the onset of LH surge. Using this model, the present study aimed to determine the profile of follicular development and the endocrinological environment in the absence of CL with variable nadir circulating progesterone (P4) concentrations during the oestrous cycle in cattle. Luteolysis was induced in heifers and cows and they were assigned either to have the dominant follicle aspirated (CL-absent) or ovulation induced (CL-present). Ultrasound scanning to observe the diameter of each follicle and blood collection was performed from the day of follicular aspiration or ovulation and continued for 6 days. The CL-absent cattle maintained nadir circulating P4 throughout the experimental period and showed a similar diameter between the largest and second largest follicle, resulting in co-dominant follicles.
    [Show full text]
  • Efficacy of Synthetic Gonadotropin Releasing Hormone Analogs for Control of Ovulation During Estrus Synchronization Protocols
    EFFICACY OF SYNTHETIC GONADOTROPIN RELEASING HORMONE ANALOGS FOR CONTROL OF OVULATION DURING ESTRUS SYNCHRONIZATION PROTOCOLS MARK ANDREW CLINE Thesis submitted to the faculty of Virginia Polytechnic Institute and State University in partial fulfillment of the requirement for the degree of MASTER OF SCIENCE in Animal Science (Physiology of Reproduction) APPROVED: Dr. John B. Hall, Ph.D. Dr. D. Michael Denbow, Ph.D. Dr. Jim W. Knight, Ph.D. Key words: Cystorelin, Factrel, GnRH, LH, Beef cows January, 2002 Blacksburg, Virginia Tech Copyright 2002, Mark Andrew Cline EFFICACY OF SYNTHETIC GONADOTROPIN RELEASING HORMONE ANALOGS FOR CONTROL OF OVULATION DURING ESTRUS SYNCHRONIZATION PROTOCOLS by Mark Andrew Cline Department of Animal and Poultry Sciences ABSTRACT Two experiments were conducted to determine efficacy of GnRH analogs, Cystorelin (CYS, gonadorelin diacetate tytrahydrate) and Factrel (FAC, gonadorelin hydrochloride), for use in beef timed AI synchronization. In Experiment one 342 beef cows from 7 herds were assigned CYS or FAC treatment as part of the Ovsynch protocol (GnRH d 0 and 9, Lutalyse d 7). Cattle treated with FAC had greater tendency (P=.09) to be pregnant at d 45. One individual herd demonstrated FAC-treated cows had more pregnancies at day 45. In Experiment two, 18 beef cows received either CYS or FAC as part of the Ovsynch protocol, intensive blood samples, from time –30 to 525 min post GnRH, were collected at each GnRH injection. Ultrasounds were conducted daily over the course of the protocol. A treatment by phase interaction (P=.03) was found for the time to maximum LH concentration, where CYS-treated follicular cows had a shorter interval than did FAC treated follicular or luteal cows.
    [Show full text]